GlassScriptPhysician profile
Faustino Macuha
NPI 1548402423
$32,846.13
in general payments reported to CMS, 2019-2025
43 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,376 · 2020: $650 · 2021: $1,444 · 2022: $3,041 · 2023: $1,948 · 2024: $8,964 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K · Food and Beverage: $5,831 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,672 · Consulting Fee: $1,500 · Travel and Lodging: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,250.00 |
| Food and Beverage | $5,830.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,671.88 |
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $1,081.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20,098.88 | 2022-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $2,169.05 | 2021-2025 | Minimed 780g, Minimed 770g |
| Novo Nordisk INC | $2,007.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,569.58 | 2019-2025 | Evenity, Tepezza, Prolia |
| Lilly USA, LLC | $923.67 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $684.37 | 2019-2023 | Farxiga |
| Corcept Therapeutics | $429.75 | 2019-2022 | |
| Dexcom, INC. | $332.07 | 2022-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $304.04 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $258.31 | 2021-2022 | |
| Janssen Biotech, INC. | $257.46 | 2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $257.36 | 2019-2025 | |
| Averitas Pharma INC. | $251.28 | 2024-2025 | Qutenza |
| Genzyme Corporation | $245.00 | 2020 | |
| Xeris Pharmaceuticals, INC. | $226.85 | 2022-2025 | Recorlev, Gvoke Hypopen |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faustino Macuha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.